

ROTHWELL, FIGG, ERNST & MANBECK

1425 K Street, NW
Suite 800
Washington, D.C. 20005

Telephone: (202)783-6040
Telefax: (202)783-6031

RECEIVED
CENTRAL FAX CENTER

JUN 02 2005

FACSIMILE TRANSMITTAL SHEET

DATE: June 2, 2005

TO: Examiner Matthew Fedowitz
U.S. Patent and Trademark Office

Re: 10/691,528
Our Ref.: 2923-576

Fax No.: 571 273 3105

FROM: Monica Chin Kitts

Number of Pages Including This Transmittal Sheet: 2

If any problems in connection with this facsimile, please contact: Cindy 202-624-1584

THIS MESSAGE IS INTENDED FOR THE USE OF THE INDIVIDUAL OR ENTITY TO WHICH IT IS ADDRESSED AND MAY CONTAIN INFORMATION THAT IS PRIVILEGED, CONFIDENTIAL AND EXEMPT FROM DISCLOSURE UNDER APPLICABLE LAW. IF THE READER OF THIS MESSAGE IS NOT THE INTENDED RECIPIENT OR THE EMPLOYEE OR AGENCY RESPONSIBLE FOR DELIVERING THE MESSAGE TO THE INTENDED RECIPIENT, YOU ARE HEREBY NOTIFIED THAT ANY DISSEMINATION, DISTRIBUTION OR COPYING OF THIS COMMUNICATION IS STRICTLY PROHIBITED. IF YOU HAVE RECEIVED THIS COMMUNICATION IN ERROR, PLEASE NOTIFY US IMMEDIATELY BY TELEPHONE AND RETURN THE ORIGINAL MESSAGE TO US AT THE ABOVE ADDRESS VIA THE U.S. POSTAL SERVICES. THANK YOU.

JUN 02 2005

002

06/02/2005 09:41 FAX 202 783 6031

ROTHWELL FIGG

INFORMATION DISCLOSURE STATEMENT BY APPLICANT				<i>Complete if Known</i>	
				Application Number	10/691,528
				Filing Date	October 24, 2003
				First Named Inventor	Wilhelm et al
				Group Art Unit	1623
				Examiner Name	Matthew L. Fedowitz
				Confirmation No.	7396
Sheet	1	of	1	Attorney Docket Number	2923-576

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published			T ²
	1.	Onkologie 2004/05, Chemotherapie			
	2.	Breastcancer.org, <u>Hormonal Therapy</u> , www.breastcancer.org/tre_sys_idx.html .			
	3.	National Cancer Institute, Cancer Facts, Tamoxifen: Questions and Answers, May 13, 2002.			
Examiner Signature				Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
¹Unique citation designation number. ²Applicant is to place a check mark here if English language Translation is attached.